Gene Therapy Lyfgenia denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for gene therapy lyfgenia are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Aetna "Not FDA-Approved" Denial for Lyfgenia — Why It Happens and How to Appeal

Lyfgenia (lovotibeglogene autotemcel) has received FDA approval for sickle cell disease. A denial citing "not FDA-approved" for this product is, in most cases, a factual error — the result of an outdated claims system lookup, a product code mismatch, or a Clinical Policy Bulletin that has not been updated to reflect the current approval status. This is one of the most straightforward denials to overturn when the correct documentation is submitted promptly.

## Why This Denial Is Appealable

Aetna's coverage policies are premised on FDA approval status. When FDA has granted approval, an insurer cannot sustain a not-approved denial without contradicting its own policy framework. Under the ACA, essential health benefit standards require plans to cover FDA-approved treatments on the same clinical basis as comparable therapies. An outdated or erroneous claim of non-approval is directly refuted by the public FDA record.

## Federal Appeal Framework

• Internal appeal: File within 180 days of denial. Aetna must respond within 30 days (standard) or 72 hours (expedited/urgent).
• External review (ACA §2719): After final internal denial, request independent external review — generally within approximately 4 months of the denial notice. IROs review without deference to Aetna's internal CPB.
• ERISA §503: For employer-sponsored plans, federal law provides a right to full-and-fair review of every adverse benefit determination.
• Expedited review: Request in writing if standard timelines would jeopardize your health.

## Documentation to Gather

1. FDA approval letter and current label: Download directly from FDA.gov. These are the primary documents disproving the not-approved claim. Attach both. 2. Date of approval: Note the FDA approval date explicitly in your appeal letter — if the denial predates a recent approval, make that clear. 3. Aetna CPB identification: Request the specific Clinical Policy Bulletin number and effective date Aetna applied. If the CPB predates FDA approval, document the discrepancy explicitly. 4. Prescriber letter: Your treating hematologist should confirm that Lyfgenia is FDA-approved for the specific indication for which it is being prescribed, and that the use is not investigational. 5. Diagnosis and treatment records: Supporting documentation that the patient's diagnosis falls within the FDA-approved indication.

## Criteria-Mapping Structure

| Aetna Denial Basis | Your Rebuttal | |---|---| | Product is not FDA-approved | FDA approval letter + current prescribing label | | CPB does not recognize product | Note CPB effective date vs. FDA approval date | | Investigational use claimed | Prescriber attestation; FDA label confirms approved indication | | Coding or lookup error | Request Aetna confirm specific code reviewed; attach correct product code |

Appeal letters that lead with the FDA approval letter — attached as Exhibit A, cited in the first paragraph — consistently achieve faster resolution of not-approved denials for gene therapy products.